|
Main features of the cobas c 513 analyser include:
• HbA1c testing for risk identification, diagnosis and monitoring of people with diabetes
• Double throughput, producing 400 patient results per hour; same footprint
• Higher on-board test capacity
• Direct results reporting
Basel, 5 October 2015: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new, dedicated high-throughput HbA1c testing solution, the cobas c 513 analyser, is now available for countries accepting the CE mark .
“The increasing number of people with diabetes is challenging healthcare providers and is putting a significant strain on healthcare systems,” said Roland Diggelmann, COO, Roche Diagnostics. “With the cobas c 513, Roche is meeting the dedicated and growing testing needs of our customers.”
With the new cobas c 513 analyser, Roche is replacing its existing dedicated HbA1c analyser, the COBAS INTEGRA 800 CTS, which has been a successful and well-established solution. The cobas c 513 analyser further increases laboratory efficiency by doubling the already market-leading throughput of the INTEGRA 800 CTS from 200 to 400 patient results per hour. The cobas c 513 achieves this performance with the same footprint.
The cobas c 513 features direct results reporting, thereby minimising the risk of result misinterpretation and eliminating the need to perform time-consuming, manual result interpretation. This saves valuable time and laboratory resources while ensuring high quality of results.
Furthermore, the cobas c 513 analyser provides a higher on-board test capacity. Enabling laboratories to load the analyser with more tests at a time saves laboratory space, releases lab resources and ensures a smooth workflow. The new analyser also offers closed tube sampling, which reduces hands-on time, prevents sample contamination and ensures operator safety for laboratory personnel. Further details about the regional launch will be provided at a later date.
| 
RSS Feed 
